IMRX - Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone

2024-03-19 02:19:36 ET

Summary

• Positive safety and anti-tumor activity released from phase 1 portion of phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors.
• Additional expansion cohort results from the phase 2 portion of the phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors, expected later in 2024.
• IMM-6-415 is another MAPK pathway targeting drug, but is able to target either RAS or RAF solid tumors; Dosing of first patient in phase 1 study expected in March 2024.
• Immuneering had $85.7 million in cash as of December 31st of 2023; Enough cash to fund its operations into the 2nd half of 2025.

Immuneering Corporation ( IMRX ) just reported positive results from the phase 1 portion of its phase 1/2 study using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors. Specifically, a huge chunk of these patients had pancreatic cancer followed by other solid tumors with this mutated expression. Initial data showed favorable safety and anti-tumor activity, along with the finding of a good recommended phase 2 dose [RP2D] to move on with. Even though this catalyst has passed that doesn't mean that investors can't yet again benefit from another one to come later on relating to this program. How so? That's because the goal of this initial study was just to look at safety, PK, PD and some anti-tumor effect of IMM-1-104. Plus, it was a basket study. The goal of this biotech is to release additional results from the expanded portion of this phase 1/2a study using this drug in 5 other cohort arms to be initiated in March of 2024....

For further details see: